dexamethasone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	826	1177-87-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexamethasone acetate decadronal neofordex	Molecular weight: 434.50 Formula: C24H31FO6 CLOGP: 2.32 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 100.90 ALOGS: -4.42 ROTB: 4 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexamethasone acetate
decadronal
neofordex

Molecular weight: 434.50
Formula: C24H31FO6
CLOGP: 2.32
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 100.90
ALOGS: -4.42
ROTB: 4

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	0.08 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 6, 1973	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutrophil count decreased	441.41	31.31	160	4218	56246	63428398
Platelet count decreased	388.55	31.31	179	4199	115943	63368701
Lymphocyte count decreased	175.01	31.31	69	4309	30188	63454456
White blood cell count decreased	174.05	31.31	112	4266	138992	63345652
Anaemia	150.74	31.31	139	4239	293291	63191353
Fracture	117.88	31.31	46	4332	19538	63465106
Plasma cell myeloma	91.11	31.31	46	4332	35859	63448785
Thrombocytopenia	68.46	31.31	67	4311	151090	63333554
Dementia	62.52	31.31	29	4349	18765	63465879
Myelosuppression	61.96	31.31	31	4347	23672	63460972
Tumour lysis syndrome	60.79	31.31	23	4355	8967	63475677
Neutropenia	51.82	31.31	62	4316	174943	63309701
Drug ineffective	51.63	31.31	6	4372	1044759	62439885
Vitiligo	50.95	31.31	13	4365	1376	63483268
Ileus	49.84	31.31	23	4355	14702	63469942
Febrile neutropenia	48.96	31.31	50	4328	118399	63366245
Renal impairment	47.28	31.31	43	4335	88312	63396332
Upper respiratory tract inflammation	43.27	31.31	13	4365	2510	63482134
Decreased appetite	41.27	31.31	67	4311	250985	63233659
Neuropathy peripheral	39.90	31.31	44	4334	113623	63371021
Pneumonia	39.63	31.31	93	4285	456674	63027970
Bone marrow failure	35.02	31.31	23	4355	29267	63455377
Osteonecrosis of jaw	33.52	31.31	24	4354	35099	63449545
Pyrexia	32.61	31.31	88	4290	470390	63014254
Renal disorder	32.55	31.31	23	4355	32951	63451693
Cardiac amyloidosis	31.66	31.31	8	4370	814	63483830
Fatigue	31.64	31.31	11	4367	888017	62596627

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	269.80	26.78	179	4559	119538	34832655
Neutrophil count decreased	230.54	26.78	120	4618	50984	34901209
Lymphocyte count decreased	107.13	26.78	55	4683	22567	34929626
White blood cell count decreased	90.41	26.78	86	4652	95359	34856834
Pneumonia	85.42	26.78	165	4573	362462	34589731
Anaemia	58.14	26.78	109	4629	233226	34718967
Dementia	55.31	26.78	30	4708	13718	34938475
Nephritis allergic	51.38	26.78	12	4726	441	34951752
Plasma cell myeloma	47.74	26.78	42	4696	41995	34910198
Bone marrow failure	43.12	26.78	34	4704	29219	34922974
Conjunctival irritation	42.38	26.78	8	4730	101	34952092
Tumour lysis syndrome	39.29	26.78	26	4712	17033	34935160
Neutropenia	38.63	26.78	73	4665	156705	34795488
Liver disorder	37.51	26.78	33	4705	32964	34919229
Thrombocytopenia	36.33	26.78	71	4667	156176	34796017
Osteonecrosis of jaw	35.81	26.78	25	4713	17864	34934329
Upper respiratory tract inflammation	35.38	26.78	12	4726	1732	34950461
Genital erythema	35.20	26.78	8	4730	260	34951933
Renal disorder	34.12	26.78	28	4710	25452	34926741
Hepatitis B DNA increased	33.99	26.78	9	4729	556	34951637
Cardiac failure	33.78	26.78	51	4687	91197	34860996
Plasmacytoma	33.16	26.78	14	4724	3677	34948516
Hepatic function abnormal	31.00	26.78	34	4704	44329	34907864
Cytopenia	30.78	26.78	20	4718	12703	34939490
Drug reaction with eosinophilia and systemic symptoms	29.74	26.78	29	4709	32983	34919210
Interstitial lung disease	29.30	26.78	40	4698	65242	34886951
Marasmus	28.83	26.78	8	4730	590	34951603
Fatigue	27.73	26.78	8	4730	370645	34581548
Myelosuppression	27.54	26.78	22	4716	19243	34932950

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	657.39	26.47	359	9040	194305	79540684
Neutrophil count decreased	642.67	26.47	281	9118	93678	79641311
Lymphocyte count decreased	257.69	26.47	121	9278	47168	79687821
White blood cell count decreased	252.58	26.47	195	9204	188093	79546896
Anaemia	185.53	26.47	244	9155	444771	79290218
Plasma cell myeloma	145.71	26.47	86	9313	53173	79681816
Fracture	122.39	26.47	57	9342	21744	79713245
Pneumonia	121.19	26.47	250	9149	659996	79074993
Dementia	112.73	26.47	56	9343	24603	79710386
Thrombocytopenia	92.85	26.47	134	9265	265125	79469864
Tumour lysis syndrome	90.96	26.47	48	9351	23891	79711098
Neutropenia	81.82	26.47	132	9267	287578	79447411
Myelosuppression	79.72	26.47	53	9346	40243	79694746
Bone marrow failure	77.26	26.47	57	9342	51050	79683939
Upper respiratory tract inflammation	74.56	26.47	25	9374	4010	79730979
Neuropathy peripheral	73.75	26.47	87	9312	141218	79593771
Renal disorder	72.90	26.47	51	9348	42054	79692935
Drug ineffective	65.61	26.47	23	9376	1080890	78654099
Plasmacytoma	64.75	26.47	23	9376	4380	79730609
Liver disorder	63.74	26.47	59	9340	72358	79662631
Osteonecrosis of jaw	62.62	26.47	47	9352	43179	79691810
Cytopenia	61.22	26.47	35	9364	20348	79714641
Fatigue	59.52	26.47	18	9381	929709	78805280
Marasmus	57.41	26.47	15	9384	1013	79733976
Cardiac failure	56.68	26.47	80	9319	154762	79580227
Hepatic function abnormal	50.19	26.47	52	9347	73055	79661934
Cardiac amyloidosis	48.78	26.47	15	9384	1825	79733164
Ileus	48.30	26.47	33	9366	26178	79708811
Nephritis allergic	47.35	26.47	12	9387	718	79734271
Pyrexia	47.34	26.47	181	9218	678528	79056461
Rash	46	26.47	161	9238	578197	79156792
Renal impairment	42.86	26.47	71	9328	157712	79577277
Febrile neutropenia	42.66	26.47	88	9311	230911	79504078
Conjunctival irritation	41.72	26.47	8	9391	128	79734861
Hepatitis B DNA increased	41.25	26.47	11	9388	804	79734185
Plasma cell leukaemia	40.82	26.47	13	9386	1773	79733216
Plasma cell myeloma recurrent	40.75	26.47	17	9382	4984	79730005
Delirium	40.66	26.47	50	9349	84577	79650412
Vitiligo	38.70	26.47	13	9386	2096	79732893
Decreased appetite	37.92	26.47	107	9292	342311	79392678
Pain	36.17	26.47	19	9380	703783	79031206
Heat illness	35.04	26.47	9	9390	568	79734421
Genital erythema	34.80	26.47	8	9391	316	79734673
Hyperuricaemia	34.73	26.47	20	9379	11779	79723210
Sepsis	34.65	26.47	89	9310	269339	79465650
Headache	34.56	26.47	17	9382	653755	79081234
Cerebral infarction	34.09	26.47	34	9365	45642	79689347
Drug reaction with eosinophilia and systemic symptoms	32.55	26.47	39	9360	64205	79670784
Dyspnoea	32.48	26.47	32	9367	856993	78877996
Interstitial lung disease	32.36	26.47	52	9347	112548	79622441
Arthralgia	31.55	26.47	14	9385	571789	79163200
Hypercalcaemia	31.28	26.47	30	9369	38400	79696589
Disseminated intravascular coagulation	31.12	26.47	29	9370	35813	79699176
Hypoalbuminaemia	30.48	26.47	23	9376	21274	79713715
Spinal compression fracture	30.41	26.47	21	9378	16937	79718052
Hyperglycaemia	29.73	26.47	39	9360	70296	79664693
C-reactive protein increased	29.72	26.47	54	9345	128973	79606016
Haemoglobin decreased	29.19	26.47	74	9325	222045	79512944
Colon cancer	28.46	26.47	19	9380	14504	79720485
Hypokalaemia	27.89	26.47	56	9343	143984	79591005

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000932	Antiemetics
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
MeSH PA	D018373	Peripheral Nervous System Agents
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:37962	adrenergic agents
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Multiple myeloma	indication	109989006	DOID:9538

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.06	acidic
pKa2	13.41	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
4017924	VUID
N0000179099	NUI
D02174	KEGG_DRUG
22690	RXNORM
4017922	VANDF
4017924	VANDF
C0057598	UMLSCUI
CHEBI:4463	CHEBI
CHEBI:41879	CHEBI
DEX	PDB_CHEM_ID
CHEMBL1651	ChEMBL_ID
CHEMBL1530428	ChEMBL_ID
DB14649	DRUGBANK_ID
C018038	MESH_SUPPLEMENTAL_RECORD_UI
DWN2WN457X	UNII
236702	PUBCHEM_CID
DB01234	DRUGBANK_ID
4552	MMSL
4553	MMSL
6112	MMSL
6848	MMSL
d00206	MMSL
002174	NDDF
002175	NDDF
109070008	SNOMEDCT_US
372584003	SNOMEDCT_US
7561000	SNOMEDCT_US
C0011777	UMLSCUI
816	INN_ID
55812-90-3	SECONDARY_CAS_RN
5743	PUBCHEM_CID
D003907	MESH_DESCRIPTOR_UI

Pharmaceutical products:

None